Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.55 |
| ▸ | ACACA | Q13085 | 4/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547569 | 0.86 | MAOB (0.54) | ACACBPPARGPPARDPPARALTA4H | |
| SCHEMBL1547697 | 0.86 | MAOB (0.54) | ACACBPPARGPPARDPPARALTA4H | |
| SCHEMBL2167110 | 0.84 | ACACB (0.53) | ACACBACACAPPARGPPARDPPARA | |
| SCHEMBL10606913 | 0.82 | MAOB (0.59) | LTA4HGAAMAOBMAPTMAOA | |
| SCHEMBL13047644 | 0.81 | ACACB (0.56) | ACACBACACAPPARGPPARDPPARA | |
| SCHEMBL18026569 | 0.80 | ACACB (0.77) | ACACBACACA | |
| SCHEMBL1547599 | 0.78 | ACACB (0.53) | ACACBACACAGAAMAOBMAPT | |
| SCHEMBL14306845 | 0.75 | FFAR1 (0.54) | ACACBACACALTA4HMAOAFFAR1 | |
| SCHEMBL3759614 | 0.75 | NR4A2 (0.63) | ACACBACACAMAOBMEN1KMT2A | |
| SCHEMBL1547629 | 0.75 | ACACB (0.56) | ACACBACACAGAAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | ACACB 7/4885ACACA 12/4885PPARG 3978/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | ACACB 5/4885ACACA 10/4885PPARG 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.